Compound · clinical trials

Glumetinib clinical trials

Also listed in trial records as SCC244

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our China, USA and Japan registers that name Glumetinib as an intervention. Synced 10 Nov 2026

4Current trials

4Recruiting now

4Lead sponsors

3Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Glumetinib is named as an intervention in 4 current clinical trials in our China, USA and Japan registers. 4 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Haihe Biopharma Co., Ltd (1). The most-studied condition is C-Met Exon 14 Mutation.

How Glumetinib works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Gastric cancerPhase 2
Gastroesophageal junction adenocarcinomaPhase 2
Colorectal cancerPhase 1/2

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594400, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11623, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Glumetinib

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting4100%

Trials by phase

Phase 1/2250%
Phase 2125%
Phase 3125%

Clinical trials of Glumetinib

4 trials

Study	Phase	Status	Lead sponsor	Registers
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs NCT06829459 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc	China
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors NCT06947291 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors	Phase 2	Recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer NCT04270591 · C-Met Exon 14 Mutation	Phase 1/2	Recruiting	Haihe Biopharma Co., Ltd	USA, China, Japan
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer NCT06980532 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Liu Huang	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Glumetinib

4 conditions

C-Met Exon 14 Mutation1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors1Non-Small Cell Lung Cancer1 Metastatic Colorectal Cancer1

By country register

Register	Trials	Recruiting
Clinical trials in China	4	4
Clinical trials in USA	1	1
Clinical trials in Japan	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Glumetinib trials

How many clinical trials are testing Glumetinib?

4 current trials in our China, USA and Japan registers name Glumetinib (also registered as SCC244) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Glumetinib trials recruiting patients?

Yes. 4 of the 4 trials are recruiting: 4 with sites in China, 1 with sites in USA and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Glumetinib clinical trials?

Haihe Biopharma Co., Ltd (1), CSPC ZhongQi Pharmaceutical Technology Co., Ltd (1), Shanghai JMT-Bio Inc (1) and Liu Huang (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Glumetinib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Glumetinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Glumetinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.